Medicure Inc. (CVE:MPH – Get Free Report)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of C$1.15 and traded as low as C$1.04. Medicure shares last traded at C$1.04, with a volume of 1,000 shares changing hands.
Medicure Stock Performance
The stock has a 50-day moving average of C$1.15 and a 200 day moving average of C$1.15. The company has a debt-to-equity ratio of 6.34, a current ratio of 1.04 and a quick ratio of 1.28. The stock has a market capitalization of C$11.17 million, a price-to-earnings ratio of -1.65 and a beta of 0.49.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
See Also
- Five stocks we like better than Medicure
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
